Understanding Cagrilintide
Share
Introduction
Cagrilintide is a long-acting amylin analog that has attracted growing interest in metabolic research, both as a standalone compound and in combination with GLP-1 receptor agonists. Its mechanism of action is distinct from incretin-based peptides, operating through the amylin receptor system to influence energy balance and glucose regulation.
Amylin and Its Receptors
Amylin (islet amyloid polypeptide, or IAPP) is a peptide hormone co-secreted with insulin by pancreatic beta cells in response to nutrient ingestion. It acts on amylin receptors — which are complexes of the calcitonin receptor with receptor activity-modifying proteins (RAMPs) — expressed in the brain, particularly in the area postrema and hypothalamus.
Amylin receptor activation produces effects complementary to GLP-1 signaling, including suppression of glucagon secretion, slowing of gastric emptying, and reduction of food intake through central satiety pathways.
Cagrilintide as a Research Compound
Native amylin has a very short half-life and a tendency to aggregate, limiting its utility as a research tool. Cagrilintide was developed as a stabilized, long-acting analog with structural modifications that prevent aggregation and extend its duration of action, making it more suitable for laboratory investigation.
Research Applications
Cagrilintide has been studied in laboratory and preclinical settings for:
- Amylin receptor pharmacology and signaling characterization
- Central nervous system mechanisms of satiety and energy homeostasis
- Complementary and additive effects when combined with GLP-1 receptor agonists
- Glucagon suppression independent of GLP-1 receptor pathways
- Gastric motility and nutrient absorption dynamics
Combination Research
One area of particular scientific interest is the combination of cagrilintide with semaglutide (sometimes referred to as CagriSema in research literature). Studies have investigated whether dual amylin and GLP-1 receptor engagement produces additive or synergistic effects on metabolic parameters, providing insight into the complementary nature of these two peptide systems.
Research Use Notice
Cagrilintide research peptide is intended strictly for in vitro and laboratory research purposes. It is not intended for human or veterinary use, therapeutic application, or clinical administration.